New Delhi, June 30 -- : Researchers from UK's RECOVERY trial (Randomised Evaluation of COVID-19 Therapy) have claimed to have found no benefit from anti-viral HIV drug-- 'lopinavir-ritonavir' administered in patients hospitalised COVID-19 patients.

With the findings of the trial, researchers opine for a revision in the treatment guidelines for those countries where 'lopinavir-ritonavir' is being used as a potential treatment for COVID-19 patients.

The University of Oxford in a press statement said that the trial Steering Committee concluded that there is no beneficial effect of lopinavir-ritonavir in patients hospitalised with COVID-19 and closed randomisation to that treatment arm.

A total of 1596 patients were randomised to lopinavir-r...